BioCardia (STU:6JU0) Cyclically Adjusted PS Ratio: (As of Sep. 04, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:6JU0 BioCardia Inc STU:6JU0
23 GF Score
Price €0.27
! 1 Warning Sign
View Full Analysis

What is BioCardia Cyclically Adjusted PS Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


BioCardia  (STU:6JU0) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


BioCardia Cyclically Adjusted PS Ratio Related Terms


BioCardia Cyclically Adjusted PS Ratio Historical Data

* Premium members only.

The historical data trend for BioCardia's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioCardia Cyclically Adjusted PS Ratio Chart

BioCardia Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.61 6.60 2.12 0.00 0.00

BioCardia Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

STU:6JU0 vs ZIVO, CYCN, LPCN: Cyclically Adjusted PS Ratio Comparison

For the Biotechnology subindustry, BioCardia's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioCardia Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioCardia's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where BioCardia's Cyclically Adjusted PS Ratio falls into.


STU:6JU0
23GF Score
BioCardia Inc STU:6JU0
Cyclically Adjusted PS Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BioCardia Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

BioCardia's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, BioCardia's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=0/333.9520*333.9520
=0.000

Current CPI (Jun. 2026) = 333.9520.

BioCardia Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 34.507 241.428 47.731
201612 -17.532 241.432 -24.250
201703 0.452 243.801 0.619
201706 0.353 244.955 0.481
201709 0.385 246.819 0.521
201712 0.297 246.524 0.402
201803 0.569 249.554 0.761
201806 0.724 251.989 0.959
201809 0.254 252.439 0.336
201812 0.317 251.233 0.421
201903 0.675 254.202 0.887
201906 0.235 256.143 0.306
201909 0.438 256.759 0.570
201912 0.428 256.974 0.556
202003 0.075 258.115 0.097
202006 0.047 257.797 0.061
202009 0.034 260.280 0.044
202012 0.043 260.474 0.055
202103 0.035 264.877 0.044
202106 0.050 271.696 0.061
202109 0.613 274.310 0.746
202112 0.062 278.802 0.074
202203 0.047 287.504 0.055
202206 0.782 296.311 0.881
202209 0.180 296.808 0.203
202212 0.082 296.797 0.092
202303 0.045 301.836 0.050
202306 0.029 305.109 0.032
202309 0.232 307.789 0.252
202312 0.008 306.746 0.009
202403 0.030 312.332 0.032
202406 0.002 314.175 0.002
202409 0.000 315.301 0.000
202412 0.000 315.605 0.000
202503 0.000 319.799 0.000
202506 0.000 322.561 0.000
202509 0.000 324.800 0.000
202512 0.000 324.054 0.000
202603 0.000 330.213 0.000
202606 0.000 333.952 0.000

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


BioCardia Business Description

Other Exchanges BCDA:USA
Address 320 Soquel Way, Sunnyvale, CA, USA, 94085
BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an off the shelf cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).
23GF Score

Get the complete analysis for STU:6JU0

Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.27
Price